Endovia Health Sciences（简称EDVA）于本周向美国证券交易委员会（SEC）提交的文件中透露，计划在未来一周内递交其Cannepil产品的FDA申请，并同时请求召开一次预提交会议（Pre-Submission Conference）。这一动态标志着该公司在推进其关键候选药物监管审批道路上迈出了重要一步。据悉，预提交会议旨在通过与FDA的早期沟通，明确申报路径中的潜在问题，从而优化后续审批流程的效率和成功率。
Endovia Health Sciences（简称EDVA）于本周向美国证券交易委员会（SEC）提交的文件中透露，计划在未来一周内递交其Cannepil产品的FDA申请，并同时请求召开一次预提交会议（Pre-Submission Conference）。这一动态标志着该公司在推进其关键候选药物监管审批道路上迈出了重要一步。据悉，预提交会议旨在通过与FDA的早期沟通，明确申报路径中的潜在问题，从而优化后续审批流程的效率和成功率。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.